Melanoma/Skin Cancer News

Two randomized phase 3 trials of pembrolizumab — one in lung cancer and one in skin cancer — have been discontinued due to lack of efficacy, according to the agent’s manufacturer.

A novel therapeutic approach stimulated new and existing T-cell responses among patients with melanoma or non-small cell lung cancer, according to results of a phase 1 trial.

Patients with cancer who received immune checkpoint inhibitors rarely developed cardiovascular adverse events, according to results of a systematic review and meta-analysis.

Spouses of people with cancer exhibited significantly higher risk for attempted suicide and suicide death than those whose spouses had not been diagnosed with cancer, according to a nationwide cohort study in Denmark.

The lack of surgical instruments tailored for women’s hands is just one example of the gender inequity female surgeons face in the workforce.

Researchers identified a gene signature that can predict which group of patients with melanoma will experience severe immune-related adverse events when treated with immune checkpoint inhibitor therapy, according to a study.

The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with relapsed or refractory cutaneous T-cell lymphoma.

In this video, Hansa Bhargava, MD, and Victoria Barbosa, MD, MPH, MBA, FAAD, discuss the impact of UV rays on aging and the risk for skin cancer, as well as ways to protect your skin from the sun.

An immunotherapy combination improved outcomes compared with historical control for certain patients with advanced melanoma, according to a topline data announcement.

Topically applied nanoparticle-encapsulated cannabidiol cream helped prevent and repair damage to the skin from ultraviolet A radiation, according to a first-of-its-kind study.